Rapid readout: Savolitinib delivers high, durable responses in HER2‑mutant advanced NSCLC, with manageable diarrhea and strong frontline benefit signals.
Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO
Advertisement
Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, is a clinical associate professor in the Department of Clinical Oncology and the deputy medical director of the Phase 1 Clinical Trials Centre at The Chinese University of Hong Kong; as well as an honorary consultant in the Department of Clinical Oncology at the Prince of Wales Hospital/New Territories East Cluster, Hospital Authority
Articles by Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO
Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
In Vivo CAR T-Cell Therapy Drives Responses and MRD Negativity in R/R Myeloma
2
Epcoritamab Plus Lenalidomide and Rituximab Shows Consistent Efficacy Across R/R Follicular Lymphoma Subgroups
3
FDA Grants Priority Review to Adjuvant Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer
4
Azacitidine/Ivosidenib/Venetoclax Generates High ORRs in IDH1-Mutant Newly Diagnosed AML
5